Bristol-Myers Squibb Co (BMY) is Terril Brothers Inc.’s Largest Position

Terril Brothers Inc. decreased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 0.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 508,489 shares of the biopharmaceutical company’s stock after selling 3,145 shares during the quarter. Bristol-Myers Squibb makes up 10.4% of Terril Brothers Inc.’s holdings, making the stock its largest holding. Terril Brothers Inc.’s holdings in Bristol-Myers Squibb were worth $32,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tradewinds Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 500 shares in the last quarter. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb during the second quarter worth about $111,000. Massey Quick Simon & CO. LLC grew its holdings in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the period. Blue Chip Partners Inc. grew its holdings in Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the period. Finally, BDO Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the second quarter worth about $123,000. Institutional investors own 69.74% of the company’s stock.

Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $61.83 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market cap of $101,200.00, a P/E ratio of 24.34, a price-to-earnings-growth ratio of 2.18 and a beta of 1.18. Bristol-Myers Squibb Co has a 1 year low of $46.01 and a 1 year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the business earned $0.77 earnings per share. sell-side analysts anticipate that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a yield of 2.59%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 62.99%.

In related news, Director Theodore R. Samuels II acquired 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

A number of equities analysts recently commented on the company. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Wednesday, October 25th. BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Vetr cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price target for the company. in a report on Friday, December 22nd. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Jefferies Group cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a report on Monday, October 16th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $65.11.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://sportsperspectives.com/2018/01/19/bristol-myers-squibb-co-bmy-is-terril-brothers-inc-s-largest-position.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply